22.52

1.05% -0.24

After Hours: 22.52

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $22.52, with a volume of 1.46M. It is down -1.05% in the last 24 hours and down -23.30% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$22.76

Open:

$22.48

24h Volume:

1.46M

Relative Volume:

0.39

Market Cap:

$3.80B

Revenue:

$56.99M

Net Income/Loss:

$-107.23M

P/E Ratio:

-27.47

EPS:

-0.8199

Net Cash Flow:

$-142.55M

1W Performance:

-3.51%

1M Performance:

-23.30%

6M Performance:

+82.35%

1Y Performance:

+229.72%

1-Day Range:

$22.29

$22.94

1-Week Range:

$21.64

$23.50

52-Week Range:

$6.25

$34.39

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

137

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	22.52	3.96B	56.99M	-107.23M	-142.55M	-0.8199
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-26	Initiated	Canaccord Genuity	Buy
Feb-23-26	Initiated	Mizuho	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

Aug 20, 2026

Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus

Aug 20, 2026

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits

Aug 20, 2026

Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat

Aug 19, 2026

Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat

Aug 19, 2026

TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget

Aug 19, 2026

The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st

Aug 19, 2026

Aug 18, 2026

Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet

Aug 18, 2026

Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat

Aug 18, 2026

H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada

Aug 18, 2026

H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com

Aug 18, 2026

Aug 17, 2026

Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Aug 17, 2026

Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com

Aug 17, 2026

Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Aug 16, 2026

Early trial shows strong pancreatic cancer resp... - Pluang

Aug 16, 2026

Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha

Aug 16, 2026

Aug 15, 2026

Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat

Aug 15, 2026

Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan

Aug 14, 2026

Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan

Aug 14, 2026

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - Stock Titan

Aug 14, 2026

Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan

Aug 14, 2026

Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan

Aug 14, 2026

Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat

Aug 14, 2026

Aug 13, 2026

Tango Therapeutics Insiders Selling US$727k In Stock Relieved As Market Cap Slides To US$4.4b - Moomoo

Aug 13, 2026

Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat

Aug 13, 2026

Tango Therapeutics (NASDAQ:TNGX): What Does the Latest Update Mean for Clinical Progress? - Kalkine Media

Aug 13, 2026

Aug 12, 2026